BlackRock’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-878,324
| Closed | -$16.1M | – | 5419 |
|
|
2020
Q4 | $16.1M | Buy |
878,324
+20,990
| +2% | +$383K | ﹤0.01% | 3122 |
|
|
2020
Q3 | $15.7M | Sell |
857,334
-1,256
| -0.1% | -$21.1K | ﹤0.01% | 2999 |
|
|
2020
Q2 | $12.9M | Buy |
858,590
+54,218
| +7% | +$774K | ﹤0.01% | 3043 |
|
|
2020
Q1 | $12.7M | Sell |
804,372
-5,710
| -0.7% | -$92.3K | ﹤0.01% | 2862 |
|
|
2019
Q4 | $13.2M | Buy |
810,082
+32,720
| +4% | +$546K | ﹤0.01% | 3112 |
|
|
2019
Q3 | $11.6M | Buy |
777,362
+27,668
| +4% | +$373K | ﹤0.01% | 3136 |
|
|
2019
Q2 | $12.4M | Buy |
749,694
+103,540
| +16% | +$1.69M | ﹤0.01% | 3126 |
|
|
2019
Q1 | $11.2M | Sell |
646,154
-11,844
| -2% | -$215K | ﹤0.01% | 3062 |
|
|
2018
Q4 | $11.6M | Buy |
657,998
+23,992
| +4% | +$407K | ﹤0.01% | 3006 |
|
|
2018
Q3 | $11.5M | Buy |
634,006
+45,154
| +8% | +$926K | ﹤0.01% | 3167 |
|
|
2018
Q2 | $11.5M | Buy |
588,852
+499,237
| +557% | +$9.35M | ﹤0.01% | 3168 |
|
|
2018
Q1 | $1.57M | Sell |
89,615
-1,717
| -2% | -$31.4K | ﹤0.01% | 3755 |
|
|
2017
Q4 | $1.03M | Sell |
91,332
-90
| -0.1% | -$940 | ﹤0.01% | 3893 |
|
|
2017
Q3 | $973K | Sell |
91,422
-1,086
| -1% | -$10.3K | ﹤0.01% | 3917 |
|
|
2017
Q2 | $810K | Sell |
92,508
-511,143
| -85% | -$4.5M | ﹤0.01% | 3897 |
|
|
2017
Q1 | $7.12M | Buy |
603,651
+601,936
| +35,098% | +$7.31M | ﹤0.01% | 3259 |
|
|
2016
Q4 | $22K | Sell |
1,715
-109
| -6% | -$1.46K | ﹤0.01% | 3235 |
|
|
2016
Q3 | $27K | Buy |
1,824
+262
| +17% | +$3.72K | ﹤0.01% | 3214 |
|
|
2016
Q2 | $19K | Buy |
1,562
+959
| +159% | +$15.4K | ﹤0.01% | 3286 |
|
|
2016
Q1 | $12K | Buy |
603
+361
| +149% | +$5.98K | ﹤0.01% | 3091 |
|
|
2015
Q4 | $5K | Hold |
242
| – | – | ﹤0.01% | 3176 |
|
|
2015
Q3 | $4K | Hold |
242
| – | – | ﹤0.01% | 3099 |
|
|
2015
Q2 | $9K | Buy |
+242
| New | +$7.81K | ﹤0.01% | 2889 |
|
BlackRock's CBMG Position: Q1 2021 in Review
BlackRock sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 878,324 shares — an estimated $16.1M sold.
BlackRock first reported a position in CBMG in Q2 2015 and held it in 23 quarters. The position peaked at $16.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- BlackRock reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- BlackRock sold 878,324 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $16.1M.
- BlackRock first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 23 quarters.
- BlackRock's Cellular Biomedicine Group, Inc. position peaked at $16.1M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on BlackRock's 13F filing for Q1 2021, filed 7 May 2021.